A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

NCT02184611 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

308

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Umeclidinium bromide
DRUG: Placebo

Sponsor

GlaxoSmithKline